{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:02:32Z","timestamp":1794578552513,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,22]]},"DOI":"10.7759\/cureus.47493","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T05:06:41Z","timestamp":1698037601000},"source":"Crossref","is-referenced-by-count":7,"title":["Saroglitazar in Non-alcoholic Fatty Liver Disease From Bench to Bedside: A Comprehensive Review and Sub-group Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Akash","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikram","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suprabhat","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Goenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154822","article-title":"Preparing for the NASH epidemic: a call to action","volume":"122","author":"Kanwal F","year":"2021","unstructured":"Kanwal F, Shubrook JH, Younossi Z, et al.. Preparing for the NASH epidemic: a call to action. Metabolism. 2021, 122:154822. 10.1016\/j.metabol.2021.154822","journal-title":"Metabolism"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi Z","year":"2019","unstructured":"Younossi Z, Tacke F, Arrese M, et al.. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019, 69:2672-82. 10.1002\/hep.30251","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal AJ","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al.. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010, 362:1675-85. 10.1056\/NEJMoa0907929","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2174\/13894501113149990199","article-title":"The first approved agent in the Glitazar\u2019s class: saroglitazar","volume":"15","author":"Agrawal R","year":"2014","unstructured":"Agrawal R. The first approved agent in the Glitazar\u2019s class: saroglitazar. Curr Drug Target. 2014, 15:151-5. 10.2174\/13894501113149990199","journal-title":"Curr Drug Target"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind Phase 2 trial","volume":"74","author":"Gawrieh S","year":"2021","unstructured":"Gawrieh S, Noureddin M, Loo N, et al.. Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind Phase 2 trial. Hepatology. 2021, 74:1809-24. 10.1002\/hep.31843","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A phase 2 double blinded, randomized controlled trial of Saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui MS","year":"2021","unstructured":"Siddiqui MS, Idowu MO, Parmar D, et al.. A phase 2 double blinded, randomized controlled trial of Saroglitazar in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2021, 19:2670-2. 10.1016\/j.cgh.2020.10.051","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-3467(07)60142-6","article-title":"Writing narrative literature reviews for peer-reviewed journals: secrets of the trade","volume":"5","author":"Green BN","year":"2006","unstructured":"Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med. 2006, 5:101-17. 10.1016\/S0899-3467(07)60142-6","journal-title":"J Chiropr Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque S","year":"2021","unstructured":"Francque S, Szabo G, Abdelmalek MF, et al.. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol. 2021, 18:24-39. 10.1038\/s41575-020-00366-5","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084305","article-title":"PPAR-targeted therapies in the treatment of non-alcoholic fatty liver disease in diabetic patients","volume":"23","author":"Lange NF","year":"2022","unstructured":"Lange NF, Graf V, Caussy C, Dufour JF. PPAR-targeted therapies in the treatment of non-alcoholic fatty liver disease in diabetic patients. Int J Mol Sci. 2022, 23:4305. 10.3390\/ijms23084305","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2005.06.010","article-title":"Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands","volume":"344","author":"Seimandi M","year":"2005","unstructured":"Seimandi M, Lemaire G, Pillon A, et al.. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem. 2005, 344:8-15. 10.1016\/j.ab.2005.06.010","journal-title":"Anal Biochem"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0584-2","article-title":"Effect of food on the pharmacokinetics of saroglitazar magnesium, a novel dual ppar\u03b1\u03b3 agonist, in healthy adult subjects","volume":"38","author":"Patel MR","year":"2018","unstructured":"Patel MR, Kansagra KA, Parikh DP, et al.. Effect of food on the pharmacokinetics of saroglitazar magnesium, a novel dual ppar\u03b1\u03b3 agonist, in healthy adult subjects. Clin Drug Investig. 2018, 38:57-65. 10.1007\/s40261-017-0584-2","journal-title":"Clin Drug Investig"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul U","year":"2019","unstructured":"Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, Jaiswal A. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc Diabetol. 2019, 18:80. 10.1186\/s12933-019-0884-3","journal-title":"Cardiovasc Diabetol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-021-00524-8","article-title":"Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis","volume":"22","author":"Akbari R","year":"2021","unstructured":"Akbari R, Behdarvand T, Afarin R, Yaghooti H, Jalali MT, Mohammadtaghvaei N. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis. BMC Pharmacol Toxicol. 2021, 22:53. 10.1186\/s40360-021-00524-8","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-019-00967-6","article-title":"Saroglitazar deactivates the hepatic LPS\/TLR4 signaling pathway and ameliorates adipocyte dysfunction in rats with high-fat emulsion\/LPs model-induced non-alcoholic steatohepatitis","volume":"42","author":"Hassan NF","year":"2019","unstructured":"Hassan NF, Nada SA, Hassan A, El-Ansary MR, Al-Shorbagy MY, Abdelsalam RM. Saroglitazar deactivates the hepatic LPS\/TLR4 signaling pathway and ameliorates adipocyte dysfunction in rats with high-fat emulsion\/LPs model-induced non-alcoholic steatohepatitis. Inflammation. 2019, 42:1056-70. 10.1007\/s10753-019-00967-6","journal-title":"Inflammation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin Resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease","volume":"10","author":"Kumar DP","year":"2020","unstructured":"Kumar DP, Caffrey R, Marioneaux J, et al.. The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin Resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease. Sci Rep. 2020, 10:9330. 10.1038\/s41598-020-66458-z","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112357","article-title":"Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids","volume":"144","author":"Sarkar S","year":"2021","unstructured":"Sarkar S, Kumari D, Gupta SK, et al.. Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids. Biomed Pharmacother. 2021, 144:112357. 10.1016\/j.biopha.2021.112357","journal-title":"Biomed Pharmacother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13634","article-title":"Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain MR","year":"2018","unstructured":"Jain MR, Giri SR, Bhoi B, et al.. Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 2018, 38:1084-94. 10.1111\/liv.13634","journal-title":"Liver Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10530-0","article-title":"Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL\/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet","volume":"23","author":"Giri SR","year":"2023","unstructured":"Giri SR, Bhoi B, Trivedi C, et al.. Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL\/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet. BMC Cancer. 2023, 23:59. 10.1186\/s12885-023-10530-0","journal-title":"BMC Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2021.06.015","article-title":"Saroglitazar for nonalcoholic fatty liver disease: a single centre experience in 91 patients","volume":"12","author":"Padole P","year":"2022","unstructured":"Padole P, Arora A, Sharma P, Chand P, Verma N, Kumar A. Saroglitazar for nonalcoholic fatty liver disease: a single centre experience in 91 patients. J Clin Exp Hepatol. 2022, 12:435-9. 10.1016\/j.jceh.2021.06.015","journal-title":"J Clin Exp Hepatol"},{"key":"ref21","article-title":"Role of Saroglitazar in non diabetic non alcoholic fatty liver disease patients: a retrospective observational study","volume":"15","author":"Jaiswal A","year":"2021","unstructured":"Jaiswal A, Jain K, Singh AK. Role of Saroglitazar in non diabetic non alcoholic fatty liver disease patients: a retrospective observational study. J Clin Diagnosis Res. 2021, 15:OC21-23.","journal-title":"J Clin Diagnosis Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4287075","article-title":"Clinical case series of decrease in shear wave elastography values in ten diabetic dyslipidemia patients having NAFLD with Saroglitazar 4 mg: an Indian experience","volume":"2020","author":"Roy S","year":"2020","unstructured":"Roy S. Clinical case series of decrease in shear wave elastography values in ten diabetic dyslipidemia patients having NAFLD with Saroglitazar 4 mg: an Indian experience. Case Rep Med. 2020, 2020:4287075. 10.1155\/2020\/4287075","journal-title":"Case Rep Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2021.03.012","article-title":"Safety and efficacy of Saroglitazar in nonalcoholic fatty liver patients with diabetic dyslipidemia-a prospective, interventional, pilot study","volume":"12","author":"Rajesh NA","year":"2022","unstructured":"Rajesh NA, Drishya L, Ambati MM, et al.. Safety and efficacy of Saroglitazar in nonalcoholic fatty liver patients with diabetic dyslipidemia-a prospective, interventional, pilot study. J Clin Exp Hepatol. 2022, 12:61-7. 10.1016\/j.jceh.2021.03.012","journal-title":"J Clin Exp Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal O","year":"2020","unstructured":"Goyal O, Nohria S, Goyal P, Kaur J, Sharma S, Sood A, Chhina RS. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep. 2020, 10:21117. 10.1038\/s41598-020-78342-x","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9065","article-title":"An observational study of reduction in glycemic parameters and liver stiffness by Saroglitazar 4 mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Mitra A","year":"2020","unstructured":"Mitra A. An observational study of reduction in glycemic parameters and liver stiffness by Saroglitazar 4 mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Cureus. 2020, 12:e9065. 10.7759\/cureus.9065","journal-title":"Cureus"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: a tertiary care center experience","volume":"7","author":"Chaudhuri S","year":"2023","unstructured":"Chaudhuri S, Dutta A, Chakraborty SB. Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: a tertiary care center experience. JGH Open. 2023, 7:215-20. 10.1002\/jgh3.12878","journal-title":"JGH Open"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.01.018","article-title":"Saroglitazar, a dual PPAR \u03b1\/\u03b3 agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis","volume":"21","author":"Siddiqui MS","year":"2023","unstructured":"Siddiqui MS, Parmar D, Sheikh F, et al.. Saroglitazar, a dual PPAR \u03b1\/\u03b3 agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis. Clin Gastroenterol Hepatol. 2023, 21:2597-605.e2. 10.1016\/j.cgh.2023.01.018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/LVT.0000000000000110","article-title":"Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients","volume":"29","author":"Siddiqui MS","year":"2023","unstructured":"Siddiqui MS, Parmar D, Shaikh F, et al.. Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients. Liver Transpl. 2023, 29:979-86. 10.1097\/LVT.0000000000000110","journal-title":"Liver Transpl"},{"key":"ref29","article-title":"An investigator initiated prospective, single arm observational study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)","volume":"6","author":"Hajare SD","year":"2019","unstructured":"Hajare SD, Gokak VP, Ghorpade S, Patil A, Jadhav A. An investigator initiated prospective, single arm observational study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH). Int J Contemp Med Res. 2019, 6:","journal-title":"Int J Contemp Med Res"},{"key":"ref30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2023.07.188","article-title":"Safety and efficacy of dual PPAR-alpha agonist, saroglitazar, in management of NAFLD with diabetes and\/or dyslipidemia in liver transplant recipients","volume":"13","author":"Dhampalwar S","year":"2023","unstructured":"Dhampalwar S, Choudhary NS, Saraf N, Bhangui P, Rastogi A, Soin A. Safety and efficacy of dual PPAR-alpha agonist, saroglitazar, in management of NAFLD with diabetes and\/or dyslipidemia in liver transplant recipients. J Clin Exp Hepatol. 2023, 13:S132-3.","journal-title":"J Clin Exp Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29797","article-title":"Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy C","year":"2018","unstructured":"Caussy C, Reeder SB, Sirlin CB, Loomba R. Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018, 68:763-72. 10.1002\/hep.29797","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102174","article-title":"Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"47","author":"Bandyopadhyay S","year":"2023","unstructured":"Bandyopadhyay S, Samajdar SS, Das S. Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2023, 47:102174. 10.1016\/j.clinre.2023.102174","journal-title":"Clin Res Hepatol Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/190955-saroglitazar-in-non-alcoholic-fatty-liver-disease-from-bench-to-bedside-a-comprehensive-review-and-sub-group-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:16Z","timestamp":1707509236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/190955-saroglitazar-in-non-alcoholic-fatty-liver-disease-from-bench-to-bedside-a-comprehensive-review-and-sub-group-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,22]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.47493","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,22]]}}}